EP2847161A4 - Compositions et méthodes de traitement du diabète - Google Patents

Compositions et méthodes de traitement du diabète

Info

Publication number
EP2847161A4
EP2847161A4 EP13787016.8A EP13787016A EP2847161A4 EP 2847161 A4 EP2847161 A4 EP 2847161A4 EP 13787016 A EP13787016 A EP 13787016A EP 2847161 A4 EP2847161 A4 EP 2847161A4
Authority
EP
European Patent Office
Prior art keywords
diabetes
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13787016.8A
Other languages
German (de)
English (en)
Other versions
EP2847161A1 (fr
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellix Bio Pvt Ltd
Original Assignee
Cellix Bio Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Pvt Ltd filed Critical Cellix Bio Pvt Ltd
Publication of EP2847161A1 publication Critical patent/EP2847161A1/fr
Publication of EP2847161A4 publication Critical patent/EP2847161A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP13787016.8A 2012-05-08 2013-01-29 Compositions et méthodes de traitement du diabète Withdrawn EP2847161A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1788CH2012 2012-05-08
PCT/IB2013/050744 WO2013167987A1 (fr) 2012-05-08 2013-01-29 Compositions et méthodes de traitement du diabète

Publications (2)

Publication Number Publication Date
EP2847161A1 EP2847161A1 (fr) 2015-03-18
EP2847161A4 true EP2847161A4 (fr) 2015-12-23

Family

ID=54193689

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13787016.8A Withdrawn EP2847161A4 (fr) 2012-05-08 2013-01-29 Compositions et méthodes de traitement du diabète

Country Status (8)

Country Link
EP (1) EP2847161A4 (fr)
JP (1) JP2015521174A (fr)
CN (1) CN104364230A (fr)
AU (1) AU2013257708A1 (fr)
CA (1) CA2873084A1 (fr)
SG (1) SG11201407314XA (fr)
WO (1) WO2013167987A1 (fr)
ZA (1) ZA201408065B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201407307YA (en) * 2012-05-07 2014-12-30 Cellix Bio Private Ltd Prodrugs of anti-platelet agents
EP2870130A4 (fr) * 2012-07-03 2015-12-02 Cellix Bio Private Ltd Compositions et méthodes de traitement de la douleur modérée à aiguë
JPWO2022065133A1 (fr) * 2020-09-25 2022-03-31

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100184730A1 (en) * 2008-07-08 2010-07-22 Vu Chi B Fatty Acid Acylated Salicylates and Their Uses
US20110082192A1 (en) * 2009-10-05 2011-04-07 Milne Jill C Lipoic acid acylated salicylate derivatives and their uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03003575A (es) * 2000-10-24 2003-07-14 Ajinomoto Kk Procedimiento para elaborar la forma b del cristal de nateglinida.
AU2003242520A1 (en) * 2002-04-15 2003-10-27 Novartis Ag Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100184730A1 (en) * 2008-07-08 2010-07-22 Vu Chi B Fatty Acid Acylated Salicylates and Their Uses
US20110082192A1 (en) * 2009-10-05 2011-04-07 Milne Jill C Lipoic acid acylated salicylate derivatives and their uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2013167987A1 *
SHINKAI H ET AL: "N-(CYCLOHEXYLCARBONYL)-D-PHENYLALANINES AND RELATED COMPOUNDS. A NEW CLASS OF ORAL HYPOGLYCEMIC AGENTS. 2", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 32, no. 7, 1 January 1989 (1989-01-01), pages 1436 - 1441, XP001172441, ISSN: 0022-2623, DOI: 10.1021/JM00127A006 *

Also Published As

Publication number Publication date
CA2873084A1 (fr) 2013-11-14
WO2013167987A1 (fr) 2013-11-14
ZA201408065B (en) 2016-04-28
SG11201407314XA (en) 2014-12-30
AU2013257708A1 (en) 2014-12-04
JP2015521174A (ja) 2015-07-27
EP2847161A1 (fr) 2015-03-18
CN104364230A (zh) 2015-02-18

Similar Documents

Publication Publication Date Title
IL266582A (en) Compositions and methods for the treatment of hemoglobinopathies
HK1251796A1 (zh) 治療糖尿病的方法和組合物
EP2847152A4 (fr) Compositions et méthodes de traitement du syndrome métabolique
HK1209633A1 (en) Compositions and methods for treating diabetes
IL238177A0 (en) Methods and preparations for the treatment of cancer
ZA201408056B (en) Compositions and methods for the treatment of mucositis
EP2867239A4 (fr) Oxabicycloheptanes et oxabicycloheptènes pour le traitement du diabète
HK1202458A1 (en) Glucokinase activator compositions for the treatment of diabetes
SG11201509782TA (en) Compositions and methods for the treatment of diabetes and pre-diabetes
IL234606A0 (en) Innovative methods and compounds for the treatment of diseases
ZA201408055B (en) Compositions and methods for the treatment of local pain
HRP20181761T1 (hr) Novi pripravak alfentanila za liječenje akutne boli
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
EP2800568A4 (fr) Compositions, procédés d'utilisation et procédés de traitement
ZA201408065B (en) Compositions and methods for the treatment of diabetes
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
ZA201408053B (en) Compositions and methods for the treatment of metabolic syndrome
HRP20181445T1 (hr) Sastavi i postupci za liječenje dijabetesa tipa 1

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20151123

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 339/04 20060101ALI20151117BHEP

Ipc: A61P 25/00 20060101ALI20151117BHEP

Ipc: A61K 31/198 20060101AFI20151117BHEP

Ipc: A61K 31/10 20060101ALI20151117BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20160217